美国预防服务工作组:糖尿病前期与2型糖尿病筛查证据更新
对于新诊断糖尿病,强化血糖控制可改善健康结局;对于超重或肥胖的糖尿病前期人群,生活方式干预和二甲双胍可降低糖尿病发病率。
要点
- 筛查与对照组10年全因或病因特异性死亡率无显著差异。
- 新诊断糖尿病强化血糖控制可改善健康结局。
- 糖尿病前期生活方式干预和二甲双胍可降低糖尿病发病率。
核心结论
- 筛查糖尿病未显示显著死亡率获益,但评估其他健康结局的数据不足,筛查危害证据有限。
- 对新诊断(非筛查发现)的糖尿病患者,干预可改善健康结局。
- 对超重或肥胖的糖尿病前期人群,干预与糖尿病发病率降低及其他中间结局改善相关。
研究设计与样本
- 检索PubMed/MEDLINE、Cochrane图书馆和试验注册库至2019年9月,文献监测至2021年5月21日。
- 纳入评估筛查或干预的英文对照研究,对象为筛查发现或近期诊断的糖尿病前期或糖尿病患者。
主要发现
- 英国前瞻性糖尿病研究中,磺脲类或胰岛素强化血糖控制改善健康结局,20年全因死亡率相对风险0.87(95%CI 0.79-0.96)。
- 超重者二甲双胍强化血糖控制10年随访改善健康结局,全因死亡率相对风险0.64(95%CI 0.45-0.91)。
- 肥胖或超重糖尿病前期患者生活方式干预(多数>360分钟)与糖尿病发病率降低相关(23项随机对照试验;汇总相对风险0.78,95%CI 0.69-0.88)。
- 生活方式干预与收缩压和舒张压降低相关(汇总加权均数差分别为-1.7 mmHg [95%CI -2.6至-0.8]和-1.2 mmHg [95%CI -2.0至-0.4]);二甲双胍与糖尿病发病率降低相关(汇总相对风险0.73,95%CI 0.64-0.83)。
临床怎么用
- 筛查糖尿病应权衡缺乏死亡率获益及危害证据有限的现状。
- 对新诊断糖尿病患者,可考虑强化血糖控制以改善健康结局。
- 对超重或肥胖的糖尿病前期人群,推荐生活方式干预或二甲双胍以降低糖尿病发病率。
局限性
- 筛查对死亡率以外其他健康结局的证据不足。
- 筛查危害的证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Type 2 diabetes is common and is a leading cause of morbidity and disability. OBJECTIVE: To review the evidence on screening for prediabetes and diabetes to inform the US Preventive Services Task Force (USPSTF). DATA SOURCES: PubMed/MEDLINE, Cochrane Library, and trial registries through September 2019; references; and experts; literature surveillance through May 21, 2021. STUDY SELECTION: English-language controlled studies evaluating screening or interventions for prediabetes or diabetes that was screen detected or recently diagnosed. DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings; meta-analyses conducted when at least 3 similar studies were available. MAIN OUTCOMES AND MEASURES: Mortality, cardiovascular morbidity, diabetes-related morbidity, development of diabetes, quality of life, and harms. RESULTS: The review included 89 publications (N = 68 882). Two randomized clinical trials (RCTs) (25 120 participants) found no significant difference between screening and control groups for all-cause or cause-specific mortality at 10 years. For harms (eg, anxiety or worry), the trials reported no significant differences between screening and control groups. For recently diagnosed (not screen-detected) diabetes, 5 RCTs (5138 participants) were included. In the UK Prospective Diabetes Study, health outcomes were improved with intensive glucose control with sulfonylureas or insulin. For example, for all-cause mortality the relative risk (RR) was 0.87 (95% CI, 0.79 to 0.96) over 20 years (10-year posttrial assessment). For overweight persons, intensive glucose control with metformin improved health outcomes at the 10-year follow-up (eg, all-cause mortality: RR, 0.64 [95% CI, 0.45 to 0.91]), and benefits were maintained longer term. Lifestyle interventions (most involving >360 minutes) for obese or overweight persons with prediabetes were associated with reductions in the incidence of diabetes (23 RCTs; pooled RR, 0.78 [95% CI, 0.69 to 0.88]). Lifestyle interventions were also associated with improved intermediate outcomes, such as reduced weight, body mass index, systolic blood pressure, and diastolic blood pressure (pooled weighted mean difference, -1.7 mm Hg [95% CI, -2.6 to -0.8] and -1.2 mm Hg [95% CI, -2.0 to -0.4], respectively). Metformin was associated with a significant reduction in diabetes incidence (pooled RR, 0.73 [95% CI, 0.64 to 0.83]) and reduction in weight and body mass index. CONCLUSIONS AND RELEVANCE: Trials of screening for diabetes found no significant mortality benefit but had insufficient data to assess other health outcomes; evidence on harms of screening was limited. For persons with recently diagnosed (not screen-detected) diabetes, interventions improved health outcomes; for obese or overweight persons with prediabetes, interventions were associated with reduced incidence of diabetes and improvement in other intermediate outcomes.
引用
- Jonas DE, Crotty K, Yun JDY, et al. Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 34427595. doi:10.1001/jama.2021.10403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。